• Users Online: 326
  • Print this page
  • Email this page


 
 
Table of Contents
LETTER TO EDITOR
Year : 2022  |  Volume : 5  |  Issue : 1  |  Page : 188

Vemurafenib plus rituximab in relapsed or refractory hairy cell leukemia


Department of Medical Oncology, Dr. B.R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India

Date of Submission10-Jan-2022
Date of Decision22-Jan-2022
Date of Acceptance23-Jan-2022
Date of Web Publication24-Feb-2022

Correspondence Address:
Ajay Gogia
Department of Medical Oncology, Dr. B.R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi - 110 029
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/crst.crst_8_22

Rights and Permissions

How to cite this article:
Baa AK, Gogia A. Vemurafenib plus rituximab in relapsed or refractory hairy cell leukemia. Cancer Res Stat Treat 2022;5:188

How to cite this URL:
Baa AK, Gogia A. Vemurafenib plus rituximab in relapsed or refractory hairy cell leukemia. Cancer Res Stat Treat [serial online] 2022 [cited 2022 May 21];5:188. Available from: https://www.crstonline.com/text.asp?2022/5/1/188/342419



Tiacci et al. recently reported durable complete responses with the combination of vemurafenib plus rituximab in patients with relapsed and refractory hairy cell leukemia (HCL).[1] Single agent rituximab is also effective in relapsed and refractory HCL.[2] However, 55% (n = 17) of the patients in the study had not received prior rituximab therapy. Hence, independent therapeutic responses attributable to rituximab, vemurafenib, or the combination of both need to be further elucidated.

The reported incidence of the HCL variant (HCLv) in relapsed/refractory cases of HCL is 40%. HCLv has an aggressive course, and the conventional chemotherapeutic agents used in the management of HCL result in poor outcomes in cases of HCLv.[3],[4] HCLv has a similar morphological and immunophenotypic profile to HCL but have unmutated BRAF V600E and immunoglobulin rearrangement IGHV4-34. The efficacy of vemurafenib in unmutated BRAF V600E and IGHV4-34 is unknown. With 19% (n = 6) of cases in the current study being primary refractory to standard chemotherapy with a purine analog, it would be of interest to find out the proportion of cases with HCLv in this study and their responses.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
  References Top

1.
Tiacci E, De Carolis L, Simonetti E, Capponi M, Ambrosetti A, Lucia E, et al. Vemurafenib plus rituximab in refractory or relapsed hairy-cell leukemia. N Engl J Med 2021;384:1810-23.  Back to cited text no. 1
    
2.
Thomas DA, O'Brien S, Bueso-Ramos C, Faderl S, Keating MJ, Giles FJ, et al. Rituximab in relapsed or refractory hairy cell leukemia. Blood 2003;102:3906-11.  Back to cited text no. 2
    
3.
Matutes E, Martínez-Trillos A, Campo E. Hairy cell leukaemia-variant: Disease features and treatment. Best Pract Res Clin Haematol 2015;28:253-63.  Back to cited text no. 3
    
4.
Arons E, Suntum T, Stetler-Stevenson M, Kreitman RJ. VH4-34+hairy cell leukemia, a new variant with poor prognosis despite standard therapy. Blood 2009;114:4687-95.  Back to cited text no. 4
    




 

Top
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
References

 Article Access Statistics
    Viewed108    
    Printed6    
    Emailed0    
    PDF Downloaded9    
    Comments [Add]    

Recommend this journal